HomeCompareAULRF vs JNJ

AULRF vs JNJ: Dividend Comparison 2026

AULRF yields 0.06% · JNJ yields 2.14%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JNJ wins by $10.8K in total portfolio value· pulled ahead in Year 4
10 years
AULRF
AULRF
● Live price
0.06%
Share price
$113.64
Annual div
$0.07
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$19.7K
Annual income
$0.01
Full AULRF calculator →
JNJ
Johnson & Johnson
● Live price
2.14%
Share price
$242.49
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.5K
Annual income
$4,749.88
Full JNJ calculator →

Portfolio growth — AULRF vs JNJ

📍 JNJ pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAULRFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AULRF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AULRF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AULRF
Annual income on $10K today (after 15% tax)
$4.92/yr
After 10yr DRIP, annual income (after tax)
$0.01/yr
JNJ
Annual income on $10K today (after 15% tax)
$182.28/yr
After 10yr DRIP, annual income (after tax)
$4,037.40/yr
At 15% tax rate, JNJ beats the other by $4,037.39/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AULRF + JNJ for your $10,000?

AULRF: 50%JNJ: 50%
100% JNJ50/50100% AULRF
Portfolio after 10yr
$25.1K
Annual income
$2,374.94/yr
Blended yield
9.47%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

AULRF
No analyst data
Altman Z
1.6
Piotroski
8/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-5.7% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AULRF buys
0
JNJ buys
0
No recent congressional trades found for AULRF or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAULRFJNJ
Forward yield0.06%2.14%
Annual dividend / share$0.07$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%28%
Portfolio after 10y$19.7K$30.5K
Annual income after 10y$0.01$4,749.88
Total dividends collected$6.00$15.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: AULRF vs JNJ ($10,000, DRIP)

YearAULRF PortfolioAULRF Income/yrJNJ PortfolioJNJ Income/yrGap
1$10,703$2.90$10,594$274.49+$109.00AULRF
2$11,454$1.45$11,294$360.69+$160.00AULRF
3$12,256$0.72$12,133$476.91+$123.00AULRF
4← crossover$13,114$0.36$13,156$635.42$42.00JNJ
5$14,032$0.18$14,432$854.61$400.00JNJ
6$15,015$0.09$16,056$1,162.76$1.0KJNJ
7$16,066$0.05$18,175$1,604.53$2.1KJNJ
8$17,191$0.02$21,009$2,252.68$3.8KJNJ
9$18,394$0.01$24,911$3,229.73$6.5KJNJ
10$19,682$0.01$30,458$4,749.88$10.8KJNJ

AULRF vs JNJ: Complete Analysis 2026

AULRFStock

AURELIUS Equity Opportunities SE & Co. KGaA is a private equity firm specializing in acquisitions, growth, complex transaction structures/carve outs, add on acquisitions, redemption of existing creditors, management buyouts, management buy-ins, P2Ps, industry consolidation, strategic acquisitions in special target industries for existing platform investments in lower middle market companies. The firm acquires, restructures and eventually sells companies in special situations including corporate spin-offs, corporate carve-outs, platform build-up succession issues, and privately held companies with issues. It seeks to invest in company spin-offs and medium-sized companies with unresolved succession, significant operational problems, and balance sheet problems due to high debt levels. The firm considers investments in private and public companies, which are primarily operating in industrial enterprises, Industrials & chemicals, information technology, business services, lifestyle, consumer goods, food and beverage, and telecoms, media, and technology (TMT). It seeks to invest in companies headquartered in Europe with the focus on European Developed Markets & Nordic region. The firm typically invests up to €250 million ($278.97 million) and between €5 ($5.6 million) and €80 million ($89.27 million) per deal in companies with sales between €30 million ($33.5 million) and €750 million ($838.54 million) and EBITDA margin from negative to more than 15 percent. In the UK, the firm invests up to £70 million ($93.5 million) in businesses with revenues between £30 million ($34.99 million) and £1000 million ($1331.14 million). It seeks to acquire majority stake, preferably 100 percent stake in underperforming businesses with development potential. The firm prefers to invest in equity. It seeks to exit its investments through sale to private, institutional or industrial investors or through an IPO. AURELIUS Equity Opportunities SE & Co. KGaA was founded on March 20, 2006, and is based in Grünwald, Germany with additional offices in Amsterdam, Netherlands; London, United Kingdom; Madrid, Spain; Milan, Italy; Munich; Germany; Stockholm, Sweden and Dusseldorf, North Rhine-Westphalia.

Full AULRF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this AULRF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AULRF vs SCHDAULRF vs JEPIAULRF vs OAULRF vs KOAULRF vs MAINAULRF vs ABBVAULRF vs MRKAULRF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.